Presentation is loading. Please wait.

Presentation is loading. Please wait.

Scott M. Lippman, MD Director, Moores Cancer Center April 14, 2014 2014 Cancer Center Administrators Forum San Diego NCI Cancer Centers Council (C3): A.

Similar presentations


Presentation on theme: "Scott M. Lippman, MD Director, Moores Cancer Center April 14, 2014 2014 Cancer Center Administrators Forum San Diego NCI Cancer Centers Council (C3): A."— Presentation transcript:

1 Scott M. Lippman, MD Director, Moores Cancer Center April 14, 2014 2014 Cancer Center Administrators Forum San Diego NCI Cancer Centers Council (C3): A Model for Multi ‐ Institutional Transdisciplinary Collaboration

2 Evolution of the Moores Cancer Center Moores Cancer Center Opened Cancer Center Founded John Mendelsohn, Director CCSG Renewed Scott Lippman Director Awarded Comprehensive Status NCI-designated Cancer Center UCSD SOM Founded Napoleone Ferrara Basic Science Razelle Kurzrock Clinical Science Ezra Cohen Translational Science CTSA Awarded 2 CCSG Renewal ‘14 Dennis Carson Director Strategic Recruits

3 UCSD Moores Cancer Center Shared Resources Nicholas Webster, PhD Shared Resources Nicholas Webster, PhD Deputy Director Barbara Parker, MD Deputy Director Barbara Parker, MD Administration Ira Goodman, MPA, MS Administration Ira Goodman, MPA, MS Clinical Trials Office External Advisory Board Research Programs Cancer Prevention Reducing Cancer Disparities Research Programs Cancer Prevention Reducing Cancer Disparities Research Programs Hematologic Malignancies Solid Tumor Therapeutics Research Programs Hematologic Malignancies Solid Tumor Therapeutics Division of Clinical Science Razelle Kurzrock, MD Division of Clinical Science Razelle Kurzrock, MD Division of Basic Science Napoleone Ferrara, MD Division of Basic Science Napoleone Ferrara, MD Senior Advisor to the Director Thomas Kipps, MD, PhD Senior Advisor to the Director Thomas Kipps, MD, PhD Research Programs Cancer Biology & Signaling Cancer Genomics & Networks Research Programs Cancer Biology & Signaling Cancer Genomics & Networks Office of Industry Relations Executive Committee Cancer Cabinet Board of Visitors Division of Population Science John Pierce, PhD Division of Population Science John Pierce, PhD Center Director Associate Vice Chancellor for Cancer Research and Care Scott Lippman, MD Center Director Associate Vice Chancellor for Cancer Research and Care Scott Lippman, MD Shared Resources (7) Biorepository & Tissue Technology Biostatistics Genomics & Bioinformatics Microscopy Flow Cytometry Transgenic/KO Mice Diet & Physical Activity Shared Resources (7) Biorepository & Tissue Technology Biostatistics Genomics & Bioinformatics Microscopy Flow Cytometry Transgenic/KO Mice Diet & Physical Activity Shared Resources Nicholas Webster, PhD Shared Resources Nicholas Webster, PhD Division of Clinical Science Razelle Kurzrock, MD Division of Clinical Science Razelle Kurzrock, MD Division of Basic Science Napoleone Ferrara, MD Division of Basic Science Napoleone Ferrara, MD Division of Population Science John Pierce, PhD Division of Population Science John Pierce, PhD 3

4 Moores and Other Cancer Center Facilities on the UC San Diego Campus MCC Moores Cancer Center OPOutpatient Pavilion CNTCenter for Novel Therapeutics Cancer Campus Relation to Consortium Partner SDSU Altman CTRI CALM JMCHCC OP MCC CNT FACILITIES CALMCenter for Advanced Laboratory Medicine JMCJacobs Medical Center - Hospital for Cancer Care CTRIClinical and Translational Research Institute 4 SCRMSanford Consortium for Regenerative Medicine LICRLudwig Institute for Cancer Research SIOScripps Institution of Oceanography LICR SCRM SIO

5 Catchment Area 121 miles AZ Cancer Center 410 miles San Diego 8 th Largest city (1.33M) 5 th Largest county (3.14M) Imperial County Population = 175K Poverty Rate = 23% REGIONAL IMPACT UC Irvine UCLA USC City of Hope MCC 5

6 Clinical Hub of Unique Biomedical Environment UCSD MOORES THE SCRIPPS RESEARCH INSTITUTE LA JOLLA ALLERGY AND IMMUNOLOGY JCVI 2 nd largest life-sciences cluster in US (Jones Lang LaSalle) Advisory & Innovation Council Center for Novel Therapeutics (CNT) LIFE TECHNOLOGIES AMGEN JANSSEN NOVARTIS ILLUMINA PFIZER MERCK 6 SDSU 16 miles JCVI Sanford Consortium for Regenerative Medicine (opened Dec 2011; LIAI, Salk, S-B, MCC, TSRI) SDSU San Diego State University (Formal consortium MOU signed Apr 2013) (C3 MOU signed Oct 2012) J. Craig Venter Institute - HLI (opened Nov 2013; HLI MOU signed Feb 2014) SALK SANFORD | BURNHAM SCRM SALK SANFORD | BURNHAM

7 C3 MOU signed (Oct 12, 2012) MCC / C3 Formal Affiliations / Timeline SDSU: Federally-designated Hispanic-serving Institute (April 2012) C3 Retreat (June 29, 2013) Members from TSRI, LIAI & JCVI join MCC faculty Sanford Consortium for Regenerative Medicine (SCRM) opens (Dec 2011) C3 Pilot Grant RFA (Feb 28, 2014) Pedal the Cause Fundraiser (Oct 26, 2013) HLI MOU signed (Feb 2014) SDSU: Formal consortium w/ MCC MOU signed (Apr 2013) Mahajani Symposium (Sep 9, 2013) JCVI opened on UCSD Campus (Nov 2013) C3 Reception at AACR (Apr 7, 2014) C3 Pilot Grant Awards (May 1, 2014) 201220132014 Salk Gene Transfer Targeting S-B High Throughput Screening MCC Biorepository

8 C3 Steering Committee Chair (rotating) Scott M. Lippman (UCSD Moores) * Co-Chairs Tony Hunter (Salk) Garth Powis (Sanford-Burnham) * All three Institutes are represented on the AACR Board of Directors in 2014 Members Webster Cavenee (UCSD Moores) David Cheresh (UCSD Moores) Barbara Parker (UCSD Moores) Ron Evans (Salk) * Inder Verma (Salk) Geoff Wahl (Salk) Sara Courtneidge (Sanford-Burnham) Ze’ev Ronai (Sanford-Burnham) Kristiina Vuori (Sanford-Burnham) * Ira Goodman (UCSD Moores) A.D. Admin

9 Participating SRs: Negotiated an agreement to share unique resources at each institution that are unavailable at the other 2 Cancer Centers (CC) All institutions agreed to give CC members, no matter the institution, the same priority and rates as internal CC users Institutions agreed to reduce the IDC charged to users from the other 2 CC Moores:from 45% to 16% (SOM Dean agreed to waive 29% academic portion) Salk: from 95% to 16% SBMRI:from 35% to 16% CC agreed to cover IDC (16%) using developmental funds from their respective CCSGs (not part of formal agreement) All institutions agreed that standard services provided by the shared resources would not involve intellectual property C3 agreement has increased usage of the three cores by users at the other CCs during the first year C3 Resource Sharing

10 CANCER CENTERS COUNCIL Sanford | Burnham Cancer Center – High Throughput Screening Core Shared Resources Director Craig Hauser, PhD Core Leader Michael Jackson, PhD Core Users Matthew Petroski, PhD Jeffrey Smith, PhD Robert Wechsler-Reya, PhD Salk Cancer Center – Gene Transfer Targeting and Therapeutics Core Shared Resources Director James Fitzpatrick, PhD Core Leader Leszek Lisowski, PhD Core Users Jan Karlseder, PhD Ben Spike, PhD UC San Diego Moores Cancer Center – Biorepository Core Shared Resources Director Nicholas Webster, PhD Core Leader Scott VandenBerg, MD, PhD Core Users Clark Chen, MD, PhD Frank Furnari, PhD Michael Karin, PhD Andrew Lowy, MD C3 Scientific Retreat: June 29, 2013 Keynote Address Tony Hunter, PhD “Tyrosine Kinases in Cancer Biology and Treatment: Past, Present, Future”

11 Support for C3 Team Science

12 C3 Website & Pilot Grant RFA www.sdcancercouncil.org

13 C3 Pilot Grant Applications PITitleInstitutions Ball/Kang Predictive microenvironment for testing leukemia therapiesMoores/SBMRI Castro/Burkhart Targeting the Spliceosome in CLLMoores/Moores Chen/Snyder Harnessing the anti-glioblastoma activity of extracellular vesicles (EV) derived from human neural stem cells (hNSCs) Moores/SBMRI Durden/Snyder Effects of dual PI-3K/Brd4 bromodomain inhibitors on NSCs and transformed NSCsMoores/SBMRI Field/Jackson Small molecule screen for inhibitors of the GOLPH3 pathwayMoores/SBMRI Harismendy/Wechsler-Reya Mechanisms of resistance to HDAC inhibitors in medulloblastomaMoores/SBMRI Husain/Shaw Oncogene addicted metabolic reprogramming of circulating tumor cells in lung adenocarcinoma Moores/Salk Karin/Wahl Applying p38 MAPK inhibitors to tackle breast cancer metastasisMoores/Salk Li/Zhou Circulating microRNA in lung cancer early diagnosisMoores/SBMRI Lowy/Wahl Stromal reprogramming to enhance the effectiveness of pancreatic cancer therapyMoores/Salk Madlensky/Wahl Demonstrating the clinical utility of whole exome sequencing for cancer patientsMoores/Salk Niwa/Heynan-Genel Dissecting two distinct IRE1 RNase activities as a new therapeutic strategy in multiple myeloma and other cancers Moores/SBMRI Puri/Schwab Abl-mediated tyrosine-phosphorylation of p300 acetyl-transferase as a biomarker for tumor chemo-resistance and dasatinib-sensitivity Moores/SBMRI Rana/Ramamoorthy Identification of non-coding RNA targets in oncogenic KRAS driven colon cancerSBMRI/Moores Sicklick/Wechsler-Reya Targeting imatinib-resistant, KIT-negative cells in human GISTsMoores/SBMRI Strongin/Bouvet PTK7 pseudokinase, a novel marker and a drug target in metastatic cancerSBMRI/Moores Yu/Rana APOBEC deaminases in primary and metastatic melanomaMoores/SBMRI Field/Jackson Small molecule screen for inhibitors of the GOLPH3 pathwayMoores/SBMRI Lowy/Wahl Stromal reprogramming to enhance the effectiveness of pancreatic cancer therapyMoores/Salk new

14 Scott M. Lippman, MD Director, Moores Cancer Center Chugai Pharmaceutical Chair, Professor of Medicine Associate Vice Chancellor for Cancer Research and Care San Diego NCI Cancer Centers Council (C3): A Model for Multi ‐ Institutional Transdisciplinary Collaboration


Download ppt "Scott M. Lippman, MD Director, Moores Cancer Center April 14, 2014 2014 Cancer Center Administrators Forum San Diego NCI Cancer Centers Council (C3): A."

Similar presentations


Ads by Google